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Abstract
Cardiovascular complications, characterized by endothelial dysfunction and accelerated
atherosclerosis, are the leading cause of morbidity and mortality associated with diabetes. There is
growing evidence that excess generation of highly reactive free radicals, largely due to
hyperglycemia, causes oxidative stress, which further exacerbates the development and
progression of diabetes and its complications. Overproduction and/or insufficient removal of these
free radicals result in vascular dysfunction, damage to cellular proteins, membrane lipids and nucleic
acids. Despite overwhelming evidence on the damaging consequences of oxidative stress and its
role in experimental diabetes, large scale clinical trials with classic antioxidants failed to
demonstrate any benefit for diabetic patients. As our understanding of the mechanisms of free
radical generation evolves, it is becoming clear that rather than merely scavenging reactive radicals,
a more comprehensive approach aimed at preventing the generation of these reactive species as
well as scavenging may prove more beneficial. Therefore, new strategies with classic as well as new
antioxidants should be implemented in the treatment of diabetes.
Introduction
It is a well-established fact that diabetes is a risk factor for
cardiovascular disease [1,2]. While microvascular compli-
cations of diabetes include nephropathy and retinopathy,
macrovascular complications resulting in atherosclerotic
cardiovascular disease such as coronary artery disease, cer-
ebrovascular disease and peripheral vascular disease are
the leading cause of death in the diabetic population
[3,4]. The Diabetes Control and Complications trial
(DCCT) demonstrated that tight control of blood glucose
is effective in reducing clinical complications signifi-
cantly, but even optimal control of blood glucose could
not prevent complications suggesting that alternative
treatment strategies are needed [4]. Since numerous stud-
ies demonstrated that oxidative stress, mediated mainly
by hyperglycemia-induced generation of free radicals,
contributes to the development and progression of diabe-
tes and related contributions, it became clear that amelio-
rating oxidative stress through treatment with
antioxidants might be an effective strategy for reducing
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diabetic complications. To this end, several clinical trials
investigated the effect of the antioxidant vitamin E on the
prevention of diabetic complications. However, these tri-
als failed to demonstrate relevant clinical benefits of this
antioxidant on cardiovascular disease [5-7]. The negative
results of the clinical trials with antioxidants prompted
new studies focusing on the mechanisms of oxidative
stress in diabetes in order to develop causal antioxidant
therapy. In this article, sources of free radicals contribut-
ing to oxidative stress and the natural defense mecha-
nisms in diabetes are briefly reviewed. Experimental and
clinical evidence with respect to the use of conventional
antioxidants in diabetes is summarized and causal ther-
apy approaches with novel antioxidants are discussed.
What is oxidative stress?
Oxidative stress is defined in general as excess formation
and/or insufficient removal of highly reactive molecules
such as reactive oxygen species (ROS) and reactive nitro-
gen species (RNS) [8,9]. ROS include free radicals such as
superoxide (•O2
-), hydroxyl (•OH), peroxyl (•RO2),
hydroperoxyl (•HRO2
-) as well as nonradical species such
as hydrogen peroxide (H2O2) and hydrochlorous acid
(HOCl) [8,10]. RNS include free radicals like nitric oxide
(•NO) and nitrogen dioxide (•NO2
-), as well as nonradi-
cals such as peroxynitrite (ONOO-), nitrous oxide
(HNO2) and alkyl peroxynitrates (RONOO) [8,10]. Of
these reactive molecules, •O2
-, •NO and ONOO- are the
most widely studied species and play important roles in
the diabetic cardiovascular complications. Thus, these
species will be discussed in more detail.
•NO is normally produced from L-arginine by endothelial
nitric oxide synthase (eNOS) in the vasculature [8]. •NO
mediates endothelium-dependent vasorelaxation by its
action on guanylate cyclase in vascular smooth muscle
cells (VSMC), initiating a cascade that leads to vasorelaxa-
tion.  •NO also displays antiproliferative properties and
inhibits platelet and leukocyte adhesion to vascular
endothelium [8]. Therefore, •NO is considered a vasculo-
protective molecule. However, •NO easily reacts with
superoxide, generating the highly reactive molecule
ONOO-, and triggering a cascade of harmful events as dis-
cussed below [8,11]. Therefore its chemical environment,
i.e. presence of •O2
-, determines whether •NO exerts pro-
tective or harmful effects.
Production of one ROS or RNS may lead to the produc-
tion of others through radical chain reactions. As summa-
rized in Fig. 1. •O2
- is produced by one electron reduction
of oxygen by several different oxidases including
NAD(P)H oxidase, xanthine oxidase, cyclooxygenase and
even eNOS under certain conditions as well as by the
mitochondrial electron transport chain during the course
of normal oxidative phosphorylation, which is essential
for generating ATP [12-15]. Under normal conditions,
•O2
- is quickly eliminated by antioxidant defense mecha-
nisms. •O2
- is dismutated to H2O2 by manganese superox-
ide dismutase (Mn-SOD) in the mitochondria and by
copper (Cu)-SOD in the cytosol [12]. H2O2 is converted to
H20 and O2 by glutathione peroxidase (GSH-Px) or cata-
lase in the mitochondria and lysosomes, respectively.
H2O2 can also be converted to the highly reactive •OH
radical in the presence of transition elements like iron and
copper.
Why are reactive species bad?
While ROS are generated under physiological conditions
and are involved to some extent as signaling molecules
and defense mechanisms as seen in phagocytosis, neu-
trophil function, and shear-stress induced vasorelaxation,
excess generation in oxidative stress has pathological con-
sequences including damage to proteins, lipids and DNA.
These detrimental effects are briefly summarized in this
section.
ROS can stimulate oxidation of low-density lipoprotein
(LDL), and ox-LDL, which is not recognized by the LDL
receptor, can be taken up by scavenger receptors in macro-
phages leading to foam cell formation and atherosclerotic
plaques [16]. As will be discussed in greater detail in the
next section, •O2
- can activate several damaging pathways
in diabetes including accelerated formation of advanced
glycation end products (AGE), polyol pathway, hex-
osamine pathway and PKC, all of which have been proven
to be involved in micro- and macrovascular complica-
tions.  •O2
-  and H2O2  stimulate stress-related signaling
mechanisms such as NF-κ B, p38-MAPK and STAT-JAK
resulting in VSMC migration and proliferation. In
endothelial cells, H2O2 mediates apoptosis and patholog-
ical angiogenesis [15]. Furthermore, •O2
-  immediately
reacts with •NO generating cytotoxic ONOO- and this
reaction itself has several consequences. First, ONOO-
alters function of biomolecules by protein nitration as
well as causing lipid peroxidation [8]. For example, potas-
sium channels, which regulate the vasorelaxation
response, are inhibited by nitration [17,18]. As recently
reviewed by Turko et al, increased levels of nitrotyrosine
are associated with apoptosis of myocytes, endothelial
cells and fibroblasts in diabetes [8]. Second, ONOO-
causes single-strand DNA breakage which in turn activates
nuclear enzyme poly(ADP-ribose) polymerase (PARP)
[19]. Third, it decreases •NO bioavailability causing
impaired relaxation and inhibition of the antiproliferative
effects of •NO [9]. Furthermore, ONOO- oxidizes tetrahy-
drobiopterin (BH4), an important cofactor for NOS, and
causes uncoupling of NOS, which produces •O2
- instead
of •NO [9]. ROS-induced peroxidation of membrane lip-
ids alters the structure and the fluidity of biological mem-
branes, which ultimately affects function [9,13-15]. AllCardiovascular Diabetology 2005, 4:5 http://www.cardiab.com/content/4/1/5
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these pathological modifications contribute to the patho-
genesis of vascular dysfunction.
Sources of oxidative stress in diabetes
Direct evidence of oxidative stress in diabetes is based on
studies that focused on the measurement of oxidative
stress markers such as plasma and urinary F2-isoprostane
as well as plasma and tissue levels of nitrotyrosine and
•O2
- [11,20-23]. There are multiple sources of oxidative
stress in diabetes including nonenzymatic, enzymatic and
mitochondrial pathways. Thus, we will first discuss these
mechanisms and conclude with the recently proposed
working plan for the initiation of oxidative stress and
related vascular complications in diabetes.
Nonenzymatic sources of oxidative stress originate from
the oxidative biochemistry of glucose. Hyperglycemia can
directly cause increased ROS generation. Glucose can
undergo autoxidation and generate •OH radicals [8]. In
addition, glucose reacts with proteins in a nonenzymatic
manner leading to the development of Amadori products
followed by formation of AGEs. ROS is generated at mul-
tiple steps during this process. In hyperglycemia, there is
enhanced metabolism of glucose through the polyol
(sorbitol) pathway, which also results in enhanced pro-
duction of •O2
-.
Enzymatic sources of augmented generation of reactive
species in diabetes include NOS, NAD(P)H oxidase and
Generation of reactive species in diabetes Figure 1
Generation of reactive species in diabetes. Highlighted in gray are some of the most important ROS and RNS in vascular 
cells. Oxygen is converted to •O2
- via the activation of enzymatic and nonenzymatic pathways, which is then dismutated to 
H2O2 by SOD. H2O2 can be converted to H2O by catalase or glutathione peroxidase (GSH-Px) or to •OH after reaction with 
Cu or Fe. Glutathione reductase regenerates glutathione (GSH). In addition, •O2
- reacts rapidly with •NO to form ONOO-.
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xanthine oxidase [21,22,24]. All isoforms of NOS require
five cofactors/prosthetic groups such as flavin adenine
dinucleotide (FAD), flavin mononucleotide (FMN),
heme, BH4 and Ca2+-calmodulin. If NOS lacks its sub-
strate L-arginine or one of its cofactors, NOS may produce
•O2
- instead of •NO and this is referred to as the uncou-
pled state of NOS [9,21,22,24]. NAD(P)H oxidase is a
membrane associated enzyme that consists of five subu-
nits and is a major source of •O2
-  production
[21,22,25,26]. Guzik et al. investigated •O2
- levels in vas-
cular specimens from diabetic patients and probed
sources of •O2
- using inhibitors of NOS, NAD(P)H oxi-
dase, xanthine oxidase and mitochondrial electron trans-
port chain. This study demonstrated that there is
enhanced production of •O2
- in diabetes and this is pre-
dominantly mediated by NAD(P)H oxidase. Furthermore,
the NOS-mediated component is greater in patients with
diabetes than in patients who do not have diabetes [22].
We have also observed that NAD(P)H oxidase activity is
significantly higher in vascular tissue (saphenous vein and
internal mammary artery) obtained from diabetic patients
[27]. There is plausible evidence that PKC, which is stim-
ulated in diabetes via multiple mechanisms, i.e. polyol
pathway and Ang II, activates NAD(P)H oxidase [28].
The mitochondrial respiratory chain is another source of
nonenzymatic generation of reactive species. During the
oxidative phosphorylation process, electrons are trans-
ferred from electron carriers NADH and FADH2, through
four complexes in the inner mitochondrial membrane, to
oxygen, generating ATP in the process [29]. Under normal
conditions,  •O2
- is immediately eliminated by natural
defense mechanisms. A recent study demonstrated that
hyperglycemia-induced generation of •O2
- at the mito-
chondrial level is the initial trigger of vicious cycle of oxi-
dative stress in diabetes [30,31]. When endothelial cells
are exposed to hyperglycemia at the levels relevant to clin-
ical diabetes, there is increased generation of ROS and
especially  •O2
-, which precedes the activation of four
major pathways involved in the development of diabetic
complications. Nishikawa and colleagues elegantly dem-
onstrated that generation of excess pyruvate via acceler-
ated glycolysis under hyperglycemic conditions floods the
mitochondria and causes •O2
- generation at the level of
Complex II in the respiratory chain. What is more impor-
tant is that blockade of •O2
- radicals by three different
approaches using either a small molecule uncoupler of
mitochondrial oxidative phosphorylation (CCCP), over-
expression of uncoupling protein-1 (UCP1) or overex-
pression of Mn-SOD, prevented changes in NF-κ B as well
as polyol pathway, AGE formation and PKC activity.
Based on this information, it has been postulated by sev-
eral groups that mitochondrial •O2
- is the initiating snow-
ball that turns oxidative stress into an avalanche in
diabetes by stimulating more ROS and RNS production
via downstream activation of NF-κ B-mediated cytokine
production, PKC and NAD(P)H oxidase (Fig. 2). Thus,
inhibition of intracellular free radical formation would
provide a causal therapy approach in the prevention of
oxidative stress and related vascular complications in
diabetes.
Natural defense against oxidative stress and antioxidants
Reactive species can be eliminated by a number of enzy-
matic and nonenzymatic antioxidant mechanisms. As dis-
cussed above, SOD immediately converts •O2
- to H2O2,
which is then detoxified to water either by catalase in the
lysosomes or by glutathione peroxidase in the mitochon-
dria (Fig. 1). Another enzyme that is important is glutath-
ione reductase, which regenerates glutathione that is used
as a hydrogen donor by glutathione peroxidase during the
elimination of H2O2. Maritim and colleagues recently
reviewed in detail that diabetes has multiple effects on the
protein levels and activity of these enzymes, which further
augment oxidative stress by causing a suppressed defense
response [9]. For example, in the heart, which is an impor-
tant target in diabetes and prone to diabetic cardiomyop-
athy leading to chronic heart failure, SOD and glutathione
peroxidase expression as well as activity are decreased
whereas catalase is increased in experimental models of
diabetes [9,32,33]. In patients with chronic heart failure,
all three enzymes are decreased in the smooth muscle [34]
and exercise training can upregulate the expression and
activity of antioxidant enzymes. Increased isoprostane
levels in diabetic patients with chronic heart failure are
correlated with antioxidant status and disease severity
[35]. Thus, modulation of these enzymes in target organs
prone to diabetic complications such as heart and kidney
may prove beneficial in the prevention and management
of heart failure and kidney failure.
Nonenzymatic antioxidants include vitamins A, C and E;
glutathione; α -lipoic acid; carotenoids; trace elements like
copper, zinc and selenium; coenzyme Q10 (CoQ10); and
cofactors like folic acid, uric acid, albumin, and vitamins
B1, B2, B6 and B12. Alterations in the antioxidant defense
system in diabetes have recently been reviewed [11]. Glu-
tathione (GSH) acts as a direct scavenger as well as a co-
substrate for GSH peroxidase. It is a major intracellular
redox tampon system. Vitamin E is a fat-soluble vitamin
that prevents lipid peroxidation. It exists in 8 different
forms, of which α -tocopherol is the most active form in
humans. Hydroxyl radical reacts with tocopherol forming
a stabilized phenolic radical which is reduced back to the
phenol by ascorbate and NAD(P)H dependent reductase
enzymes [36,37]. CoQ10 is an endogenously synthesized
compound that acts as an electron carrier in the Complex
II of the mitochondrial electron transport chain. Brownlee
et al reported that this is the site of •O2
- generation under
hyperglycemic conditions [30,31]. CoQ10  is a lipidCardiovascular Diabetology 2005, 4:5 http://www.cardiab.com/content/4/1/5
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soluble antioxidant, and in higher concentrations, it scav-
enges •O2
- and improves endothelial dysfunction in dia-
betes [38-40]. Vitamin C (ascorbic acid) increases NO
production in endothelial cells by stabilizing NOS cofac-
tor BH4 [41]. α -Lipoic acid is a hydrophilic antioxidant
and can therefore exert beneficial effects in both aqueous
and lipid environments. α -lipoic acid is reduced to
another active compound dihydrolipoate. Dihydrolipoate
is able to regenerate other antioxidants such as vitamin C,
vitamin E and reduced glutathione through redox cycling
[41]. Thus, both experimental and clinical studies sum-
marized in the next sections utilized these naturally occur-
ring antioxidants, especially vitamins C, E and α -lipoic
acid, in order to delineate the role of oxidative stress in the
development of vascular complications of diabetes.
Evidence from experimental models
A multitude of in vivo studies have been performed utiliz-
ing antioxidants in experimental diabetic models. The
effects of antioxidants on oxidative stress are measured
through certain observable biomarkers. These markers
include the enzymatic activities of catalase, SOD, GSH-Px,
and GSH-reductase, as well as thiobarbituric acid reac-
tants (TBARS) levels, an indirect measurement of free-rad-
ical production that has been shown to be consistently
elevated in diabetes. Normalization of the activity levels
Current working model for the generation of reactive species and downstream targets in diabetes Figure 2
Current working model for the generation of reactive species and downstream targets in diabetes. Excess gen-
eration of mitochondrial ROS due to hyperglycemia initiates a vicious circle by activating stress-sensitive pathways such as NF-
κ B, p38 MAPK and Jak/STAT, polyol (sorbitol) and hexosamine pathways, PKC and AGEs. Enhanced production of AGEs, 
sorbitol and proinflammatory cytokines exerts a positive feedback on ROS and RNS synthesis and potentiates PKC-mediated 
vascular dysfunction by altering gene expression as well as vascular function and structure.
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of any of these markers, and ultimately, the balance of
free-radical production/removal, would be an effective
method to reduce ROS-induced damage. Many animal
studies have been completed with this aim in mind and
indeed have shown that diabetes-induced alterations of
oxidative stress indicators can be reversed when the ani-
mals are treated with various antioxidants. It should be
noted that a plethora of studies have been done with
numerous antioxidant compounds. We will, however,
only cover a select few within the scope of this review, spe-
cifically the compounds for which a corresponding
human clinical trial has been conducted
Mekinova et al. demonstrated that supplementation of
streptozotocin (STZ) diabetic rats with vitamins C, E, and
beta-carotene for 8 weeks produced a significant reduc-
tion of TBARS levels, GHS, and GHS-Px, an increase in Cu-
SOD, and no change in catalase activity in kidneys [42].
Treatment with vitamins C and E was also shown to
decrease urinary albumin excretion, glomerular basement
membrane thickness, and kidney weight in STZ diabetic
rats [43]. In the same study, vitamins C and E significantly
lowered malondialdehyde (TBARS) levels and GSH-Px
activity while increasing catalase and SOD activities when
compared to unsupplemented diabetic animals [43]. A
study by Cinar et el. demonstrated that supplementation
with vitamin E significantly lowered liver and lung TBARS
levels and improved impaired endothelium-dependent
vasorelaxation in STZ diabetic rat aorta [44].
α -lipoic acid, which is involved in mitochondrial dehy-
drogenase reactions, has gained a considerable amount of
attention as an antioxidant. Studies have demonstrated
that intraperitoneal administration of α -lipoic acid to STZ
diabetic Wistar rats normalizes TBARS level in plasma, ret-
ina, liver, and pancreas [45]. In the same study, Obrosova
et.al observed a reduction of GSH activity in diabetic ret-
ina and that supplementation with α -lipoic acid produced
no change [45]. However, another study demonstrated an
increase in aortic GSH-Px in STZ diabetic rats that was
normalized by treatment with α -lipoic acid [46]. Addi-
tionally, increased maximum contractile responses in dia-
betic aortic rings were ameliorated with α -lipoic acid
treatment [46].
SOD activity is undoubtedly important to the regulation
of oxidative status in diabetes. However, there is variation
as to the status of this enzyme in the diabetic state. Some
studies have reported decreased SOD activity [43,45]
while others have shown increases [47] or no change in
the enzyme [42,48]. α -lipoic acid has been observed to
normalize diabetes-induced decreases of SOD in rat heart
[48] and retina [45]. One study demonstrated that treat-
ment of STZ diabetic rats with α -lipoic acid reverses SOD-
induced vasorelaxation, potentially due to the elimina-
tion of excess superoxide/hydrogen peroxide and the
recovery of basal NO [46]. A recent study by Brands et al.
investigated the effect of oxidative stress in the develop-
ment of hypertension in diabetes using the SOD mimetic
tempol in a Type 1 model of diabetes where NOS is phar-
macologically inhibited with a NOS inhibitor, L-NAME
[49]. In this model, hyperglycemia causes hypertension
implicating an important role for NO. Results of this
study showed that if •O2
- is eliminated by tempol early in
the disease process, the hypertension and decrease in
glomerular filtration precipitated by diabetes are
prevented.
In summary, there are differences in response to antioxi-
dants in experimental diabetes in the prevention of cardi-
ovascular complications. Studies in experimental models
provide a foundation for the clinical studies but results
should be interpreted cautiously since the experimental
models of diabetes, duration and type of antioxidant
treatment and markers of oxidative stress investigated in
these studies exhibit a wide range.
Evidence from clinical trials
Although studies with antioxidants in experimental mod-
els as well as observational studies strongly suggest that
antioxidants should confer beneficial effects in reducing
cardiovascular complications in diabetes, clinical evi-
dence for the use of antioxidants is not solid. It should be
emphasized that clinical trials with antioxidants in diabe-
tes are limited and majority of these trials focused on the
use of vitamin E and C and lately α -lipoic acid. Thus, we
will attempt to group the clinical trials by the antioxidants
used.
Small trials with vitamin E demonstrated beneficial cardi-
ovascular effects. In a double-blind, placebo-controlled,
randomized study, vitamin E supplementation (1000 IU/
day) for three months in patients with Type 1 diabetes (n
= 41) significantly improved endothelium-dependent
vasorelaxation [50]. In another study, Beckman et al.
reported that administration of vitamin E (800 IU/day)
and C (1000 mg/day) combination for six months had a
positive effect on endothelium-dependent vasorelaxation
in Type 1 diabetic patients (n = 26) but had no effect in
Type 2 diabetes (n = 23) [51]. Gaede et al reported that
vitamin E (680 mg/day) and C (1250 mg/day) combina-
tion significantly improved renal function in Type 2 dia-
betes [52].
Other clinical trials on a larger scale include the Heart
Outcomes Prevention Evaluation (HOPE) trial [53], Sec-
ondary Prevention with Antioxidants of Cardiovascular
Disease in End Stage Renal Disease (SPACE) trial [54], the
Steno trial [55], the Primary Prevention Project (PPP) trial
[56] and the Study to Evaluate Carotid UltrasoundCardiovascular Diabetology 2005, 4:5 http://www.cardiab.com/content/4/1/5
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Changes in Patients Treated With Ramipril and Vitamin E
(SECURE) trial [57].
The HOPE trial enrolled patients 55 years of age or older
who were at high risk for cardiovascular disease and
recruited significant number of patients with diabetes.
This study had a 2 × 2 factorial design where in one arm
patients were randomized to vitamin E (400 IU/day) or
placebo and in the other arm of the study patients were
randomized to ramipril (10 mg/day) or placebo [53].
Results with vitamin E and ramipril were evaluated sepa-
rately as compared to respective placebo groups. In the
vitamin E arm, 4761 patients received vitamin E and 4780
patients were given placebo. In the treatment and placebo
groups, the number of patients with diabetes was 1838
and 1816, respectively. The primary endpoint was a com-
posite of myocardial infarction, stroke and death from
cardiovascular causes. The trial was stopped for ethical
reasons after 4.5 years follow-up by the recommendations
of an independent data and safety monitoring board
based on the beneficial effects of ramipril on cardiovascu-
lar events in the concurrent treatment group and lack of
effect in the vitamin E treatment group. Results of the
study were published in 2000 and demonstrated that
there was no significant difference in the primary out-
come between vitamin E and placebo groups [53]. Analy-
ses of the secondary endpoints of the study, which
included total mortality, hospitalizations for heart failure
and unstable angina, revascularization and nephropathy,
were recently published [58], and again vitamin E supple-
mentation for 4.5 years failed to provide any benefit in
cardiovascular outcomes or nephropathy. It was also
reported that there were no significant adverse events
associated with vitamin E. The HOPE trial was the largest
trial conducted thus far for the use of antioxidants in dia-
betes. The SECURE trial was designed as a substudy of the
HOPE trial to evaluate the effects of long-term treatment
with ramipril and vitamin E on atherosclerosis progres-
sion in high-risk patients. In this trial, 732 patients who
had vascular disease or diabetes were randomized to two
doses of (2.5 or 10 mg/d) ramipril and vitamin E (400 IU/
day) or placebo and progression of atherosclerosis was
monitored by B-mode carotid ultrasound. While ramipril
slowed down atherosclerotic changes, vitamin E had no
effect as compared to placebo group.
The SPACE trial recruited 196 hemodialysis patients with
preexisting cardiovascular disease who were assigned to
either placebo (n = 99) or 800 IU/day vitamin E (n = 97)
for 2 years. 43% of the patients in each group had diabe-
tes. The primary endpoint was a composite of myocardial
infarction, stroke, peripheral arterial disease or unstable
angina. There was a 46% decrease in the primary end
point events in the vitamin E group and this was mainly
due to a 70% reduction in total myocardial infarction
[54]. The PPP trial was a randomized trial again with a 2
× 2 design to evaluate the effect of low dose aspirin (100
mg/day) and vitamin E (300 mg/day) on the prevention
of cardiovascular complications in high-risk patients.
Similar to the studies discussed above, the primary end-
point was a composite of cardiovascular death, stroke or
myocardial infarction. Out of the 4784 patients recruited,
1031 had diabetes. The PPP trial was stopped prematurely
by the recommendations of an independent data and
safety monitoring board based on the consistent benefi-
cial effects of aspirin as compared to placebo group. How-
ever, there was no significant effect of vitamin E treatment
either in diabetic or nondiabetic subjects. Lastly, the
Steno-2 trial compared the effect of a multifactorial inten-
sive therapy (n = 80) with that of conventional treatment
(n = 80) on modifiable risk factors for cardiovascular dis-
ease in patients with Type 2 diabetes [55]. In the intensive
treatment group, patients received pharmacotherapy that
targeted hyperglycemia, dyslipidemia, hypertension and
microalbuminuria including daily supplementation of
vitamin C (250 mg), E (100 mg), folic acid (400 mg) and
chromium picolinate (100 mg) as well as behavior modi-
fication including low-fat diet, exercise and smoking ces-
sation. The control group received conventional therapy
as recommended in national guidelines. The intensive
therapy resulted in almost a 50% decrease in the risk of
cardiovascular events providing evidence that a multifac-
torial approach is superior to conventional therapy for the
prevention of oxidative stress-induced vascular complica-
tions in diabetes.
Studies with α -lipoic acid are approved for the treatment
of diabetic neuropathy and results are more promising
than those obtained with vitamin E. In the Alpha Lipoic
Acid in Diabetic Neuropathy (ALADIN) study, infusion of
α -lipoic acid (>600 mg) significantly improved patient
symptoms [59]. The ALADIN II Study demonstrated that
long-term (24 months) use of α -lipoic acid (600 or 1200
mg) improved nerve function [60]. ALADIN III, a rand-
omized multicenter double-blind placebo controlled
study, showed that in a cohort of 509 patients, 600 mg α -
lipoic acid administration for 6 months improved neu-
ropathy impairment score as early as 19 days, which was
maintained up to 7 months [61]. The DEKAN (Deutsche
kardiale autonome neuropathie) study evaluated the
effect of 800 mg α -lipoic acid or placebo in diabetic
patients with cardiac autonomic neuropathy for 4 months
and showed that heart rate variability, an indicator of car-
diac autonomic neuropathy, significantly improved with
α -lipoic acid treatment [62]. The SYDNEY trial investi-
gated the effect of α -lipoic acid treatment on sensory
symptoms of diabetic polyneuropathy as assessed by the
Total Symptom Score. Administration of this antioxidant
over a 3-week period improved sensory symptoms such as
pain, prickling and numbness [63]. A recent meta-analysisCardiovascular Diabetology 2005, 4:5 http://www.cardiab.com/content/4/1/5
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of trials with α -lipoic acid concluded that treatment with
intravenous  α -lipoic acid (600 mg/day) over a 3-week
period is safe and effective in improving positive neuro-
pathic symptoms as well as neuropathic deficits [64].
In summary, clinical trials with conventional antioxidants
in diabetic patients are limited. For major cardiovascular
outcomes, vitamin E failed to provide any benefit. How-
ever, when study population was limited to diabetic
patients alone as done in diabetic neuropathy trials, α -
lipoic acid has proven to be effective. As further discussed
under Perspectives, this antioxidant may be a viable
option in trials focusing on cardiovascular outcomes in
diabetes.
In addition to the many antioxidants examined above, a
number of commonly used drugs have shown promising
antioxidant activity in addition to their primary pharma-
cological activity. These drugs include thiazolidinediones
(TZDs), HMG-CoA reductase inhibitors (statins), and
inhibitors of the renin-angiotensin system.
Thiazolidinediones (TZDs) have been shown in many
animal studies to have antioxidant effect. In one study,
pioglitazone-treated rats had reduced urinary excretion of
isoprostane, a marker of oxidative stress [65]. In a trial
with type-2 diabetic rats, Bagi et al demonstrated that
treatment with rosiglitazone reduced NAD(P)H-derived
ROS and increased the activity of catalase [66]. Another
study using type-2 diabetic rats found that treatment with
troglitazone lowered hydroperoxides and decreased SOD
activity [67]. A study using troglitazone and pioglitazone
in type-2 diabetic rats found that both agents reduced
TBARS levels and increased the aortic vasorelaxation
response [68].
There is substantial evidence from in vitro studies that
statins exert an antioxidant effect. Studies have demon-
strated that statin therapy markedly reduces oxidative
stress markers (such as nitrated tyrosine) in animals [69].
Although the mechanisms for these actions are still being
elucidated, Takayama et al have demonstrated in canine
models that the antioxidant effect of statins is at least par-
tially due to inhibition of NAD(P)H oxidase [70]. Statins
have also been shown to stimulate the activity of the anti-
oxidant enzyme thioredoxin [71]. Additionally, statin
therapy has been shown to stimulate the activity of
paraoxonase (PON), which has a putative role in protect-
ing LDL from oxidation [72]. Oxidation of LDL ex vivo
has been shown to be inhibited by long-term statin ther-
apy, an effect thought to be partly due to the binding of
the statins to the LDL itself. It seems likely from the above
studies that the antioxidant actions of statins are mani-
fested via a variety of mechanisms.
Inhibitors of Angiotensin II (Ang II) activity, such as Angi-
otensin Converting Enzyme Inhibitors (ACEIs) and Angi-
otensin II receptor blockers (ARBs) have shown some
beneficial effects that may stem from their antioxidant
properties. Angiotensin II has been shown to increase
ROS levels in animal studies, through stimulation of
NAD(P)H oxidase activity [15,73]. Studies have suggested
that this effect also occurs in humans [73,74]. Ang II has
also been implicated in upregulating the expression of the
LOX-1 receptor, which is specific for oxidized LDL choles-
terol. Inhibition of the generation of Ang II, whether by
ACEI or ARB, should therefore attenuate these deleterious
processes. Indeed, Berry et al have shown that treatment
with ACEI or ARB decreases •O2
- levels in the human vas-
culature [75].
In summary, many of the agents which are a mainstay of
pharmacotherapy in diabetes have been shown to have
antioxidant properties in addition to their primary phar-
macological actions. These antioxidant properties may be
a contributing factor to the therapeutic efficacy of these
agents. Their antioxidant properties make the case for use
of these drugs even more compelling. Particularly in light
of the lackluster results seen in clinical trials with antioxi-
dant supplementation, health care providers should
redouble their efforts to ensure adequate usage of the
demonstrably effective agents summarized above.
Perspectives- Is there a role for antioxidant treatment in 
diabetes?
Although the clinical trials conducted to date failed to
provide adequate support for the use of antioxidants in
diabetes, it is still to early to reach a definitive conclusion
on this issue. As discussed above, with the exception of
alpha-lipoic acid studies in diabetic neuropathy, data
from clinical trials are limited. The majority of studies
were not designed to assess the effect of antioxidant use
specifically in diabetic patients. This is an important point
because diabetic patients represent a population in whom
oxidative stress is much higher than in the general popu-
lation. As was seen in the SPACE trial of patients on hemo-
dialysis, patients exposed to very high oxidative stress
responded favorably to vitamin E supplementation [54].
It is possible that antioxidants would be more demonstra-
bly effective in a patient population chosen on the basis
of elevated levels of oxidative stress. Unfortunately, none
of the studies to date effectively assessed the baseline oxi-
dative stress of the enrolled patients using any of the com-
monly accepted markers of inflammation.
The human trials to date used endpoints that were not
directly related to oxidative stress, but rather gross markers
of overall cardiovascular health, such as effect on mortal-
ity. The studies failed to assess the duration of the diabetic
disease states, arguably a large confounding variable. InCardiovascular Diabetology 2005, 4:5 http://www.cardiab.com/content/4/1/5
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assessing oxidative stress and the effects of antioxidants
thereon, specific markers of oxidative stress should be
measured.
With respect to the specific antioxidants studied, their
selection was based on epidemiological and observational
data, and in the absence of any solid grasp of the underly-
ing mechanisms of action. Whereas observational studies
are based on whole populations and reflect the lifelong
influence of dietary habits, most of the studies were five
years duration or less and included older patients (average
age 65.4 years). It is possible that the study populations
represented patients in whom the disease states had pro-
gressed too far to be amenable to antioxidant
intervention.
In all likelihood, the choice and dose of antioxidant might
be very important. The clinical trials focused mainly on
the use of vitamin E. Negative results with vitamins can-
not be generalized to all antioxidants. As has been elo-
quently argued elsewhere, treating the antioxidant
vitamins as a single class of compounds with expected
similar effects inappropriately disregards their wide range
of chemical properties and pharmacodynamics [76]. Clin-
ical trials to date have been conducted without any real
understanding of the mechanisms of action or the con-
centrations of the various agents seen at different physio-
logical sites. Indeed, there is not sufficient evidence to
demonstrate that vitamin E reaches target cells.
Recently, it has been postulated that antioxidant potency
of vitamins such as C and E is limited because these anti-
oxidants work as scavengers of existing excess reactive spe-
cies in a stoichiometric manner and this approach
represents a symptomatic approach to oxidative stress-
associated clinical problems [77]. Based on the new devel-
opments in our understanding of the pathophysiology of
oxidative stress, it is clear that strategies to block the for-
mation of reactive radicals will provide a targeted and
causal approach to provide conclusive evidence whether
antioxidants should be part of the cardiovascular treat-
ment plan in diabetes. Candidate agents include low
molecular weight mitochondrial and cytosolic SOD and
catalase mimetics, L-propionyl carnitine, PKC-β  inhibitor
LY-333531, peroxynitrite catalyst FP15 and mitochon-
drial uncoupler DNP [9,77,78].
Given the number of shortcomings in the clinical trials, it
seems clear that more research on the use of antioxidants
in the prevention of cardiovascular complications in dia-
betes is necessary and strongly encouraged. From a clini-
cal viewpoint, however, efforts for the prevention of
diabetic complications should seek to maximize the ben-
efits of proven therapeutic strategies including appropri-
ate life style changes and controlling blood pressure,
blood glucose and lipids.
In conclusion, the amount of evidence on the harmful
effects of oxidative stress on vascular function and the link
to pathophysiological mechanisms underlying diabetic
complications is compelling. While the lack of clinical evi-
dence on the beneficial effects of antioxidant vitamins in
diabetes management should not deter us from more
basic and clinical research on this issue, practice guide-
lines that are based on the results of numerous clinical tri-
als should be our guide to evidence-based medicine in the
prevention of cardiovascular disease in diabetes. The
recent American Heart Association science advisory on the
subject of antioxidant vitamins and cardiovascular disease
asserted that there is insufficient evidence to justify the use
of antioxidant vitamins for cardiovascular disease risk
reduction [79]. Hopefully, further research into the patho-
physiology of oxidative stress and the role of antioxidant
therapy will lead to appropriately-designed clinical trials
in which the promise of antioxidant therapy will be
realized.
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